Geron Corporation to Present at Biotechnology Industry Organization Investor Forum Business Wire
click here to return to Business Wire main menu
DonateNow





Geron Corporation to Present at Biotechnology Industry Organization Investor Forum

Business Wire - October 9, 2007


MENLO PARK, Calif. -- Geron Corporation (Nasdaq:GERN) today announced that Alan B. Colowick, Ph.D., M.P.H., president, oncology, will present an update of the company's oncology programs at 10:45 a.m. PDT on Wednesday, Oct. 10, 2007, at the Biotechnology Industry Organization Investor Forum in San Francisco.

The update will cover information about Geron's portfolio of anti-cancer therapies, including its telomerase inhibitor drug (GRN163L) and its telomerase therapeutic vaccine (GRNVAC1).

The audio and slide presentation will be available at the following website address: http://www.corporate-ir.net/ireye/confLobby.zhtml?ticker=GERN&item_id= 1657780. (Due to its length, this URL may need to be copied/pasted into your Internet browser's address field. Remove the extra space if one exists.) The replay will be available 24 hours after the live presentation and will be archived for 30 days.

Geron is developing first-in-class biopharmaceuticals for the treatment of cancer and degenerative diseases, including spinal cord injury, heart failure, diabetes and HIV/AIDS. The company is advancing an anti-cancer drug and a cancer vaccine that target the enzyme telomerase through multiple clinical trials. Geron is also the world leader in the development of human embryonic stem cell-based therapeutics, with its spinal cord injury treatment anticipated to be the first product to enter clinical development. For more information, visit www.geron.com.

---

Contacts:

Geron

David L. Greenwood, 650-473-7765

Chief Financial Officer

info@geron.com

or

Russo Partners, LLC

Media and Investors:

David Schull, 858-717-2310

david.schull@russopartnersllc.com

Tracey Milani, 619-814-3511

tracey.milani@russopartnersllc.com


071009
BW071010


Copyright © 2007 - Business Wire. All rights reserved. Reproduced with permission. Reproduction of this article (other than one copy for personal reference) must be cleared through the Business Wire, Permissions Desk, Business Wire, 1185 Avenue of the Americas, 3rd Floor, New York, NY 10036; Tel: (212) 575-8822; FAX: (212) 575-1854. http://www.businesswire.com.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Broadway Cares/Equity Fights AIDS, Elton John AIDS Foundation, the National Library of Medicine, Pacific Life Foundation and donations from users like you.

Always watch for outdated information. This article first appeared in 2007. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 2007. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .